NeoGenomics Laboratories, Inc. (NEO)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$17.38-0.46%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · NEO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On July 28, 2026, NeoGenomics, Inc. issued a press release reporting its results for its second fiscal quarter of 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed inco…
Other Events. As previously disclosed, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. The Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG-HHS”) of the internal investigation in November 2021. On July 20, 2026, the Company finalized a civil…
Other Events. As previously disclosed, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. The Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG-HHS”) of the internal investigation in November 2021. On June 20, 2026, the Company finalized a civil…
Director — Carolyn S. Starrett: The Board of Directors increased its size and appointed Carolyn S. Starrett as a new director.
Other Events. On June 17, 2026, NeoGenomics, Inc. (the “Company”) issued a press release relating to the pricing of its offering of convertible senior notes due 2032 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Convertible Notes Offering”). A copy of the press release relating to the Convertible Notes Offering is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by refere…
Other Events. On June 15, 2026, NeoGenomics, Inc. (the “Company”) issued a press release relating to the commencement of its proposed offering of convertible senior notes due 2032 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Convertible Notes Offering”). A copy of the press release relating to the Convertible Notes Offering is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorpor…
The filing is about an amendment to the equity incentive plan, not a management change.
Results of Operations and Financial Condition. On April 28, 2026, NeoGenomics, Inc. issued a press release reporting its results for its first fiscal quarter of 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed inco…
Results of Operations and Financial Condition. On February 17, 2026 , NeoGenomics, Inc. issued a press release reporting its results for its fourth fiscal quarter of 2025 and full year ended December 31, 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of th…
CFO — Jeffrey S. Sherman: The CFO is retiring with a planned transition to an advisory role and a named successor (Abhishek Jain) is being appointed, indicating an orderly succession rather than a sudden loss of leadership.
Results of Operations and Financial Condition. On January 12, 2026, NeoGenomics, Inc. (the “Company”) issued a press release announcing select preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, consisting of preliminary revenue, as well as the planned transition of Mr. Sherman from the role of Chief Financial Officer and the appointment of Abhishek Jain as the Company’s Executive Vice President, Finance. The selected financial results are b…
Director — Dr. Alison L. Hannah: The filing reports the resignation of a director and the immediate appointment of a successor to fill the vacancy, which is a routine board composition change rather than a loss of senior executive management.
Results of Operations and Financial Condition. On October 28, 2025, NeoGenomics, Inc. issued a press release reporting its results for its third fiscal quarter of 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed in…
Director — Elizabeth Floegel: A director resigned immediately without disagreement, representing a standard board departure rather than a senior executive loss.
Results of Operations and Financial Condition. On July 29, 2025, NeoGenomics, Inc. issued a press release reporting its results for its second fiscal quarter of 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed inco…
Director — Marjorie C. Green: The filing discloses the appointment of a new director to fill a vacancy created by a board size increase, which is a routine governance action rather than an executive departure.
The filing discloses an amendment to the company's equity incentive plan, which is a compensatory arrangement rather than a change in management personnel.
Results of Operations and Financial Condition. On April 29, 2025, NeoGenomics, Inc. issued a press release reporting its results for its first fiscal quarter of 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed inco…
CEO — Mr. Zook: The filing discloses the appointment of Mr. Zook as Chief Executive Officer and the terms of his new employment agreement, which is a significant executive hire rather than a departure.
President & Chief Operating Officer — Warren Stone: The filing primarily announces the internal promotion of Warren Stone to President & COO, accompanied by a role elimination for another executive, which is a standard succession/structural change rather than a sudden loss of a top executive.
President & Chief Operating Officer — Warren Stone: The filing primarily announces the internal promotion of Warren Stone to President & COO, which is a positive signal of succession planning, despite the concurrent elimination of the previous COO role.
Results of Operations and Financial Condition. On February 18, 2025 , NeoGenomics, Inc. issued a press release reporting its results for its fourth fiscal quarter of 2024 and full year ended December 31, 2024. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of th…
CFO — Jeffrey Sherman: The filing discloses the payment of retention bonuses to senior executives, which is a compensatory arrangement rather than a change in management status or departure.
CEO — Christopher Smith: The CEO is retiring with a named successor (Tony Zook) and a transition plan, constituting an orderly succession rather than a sudden loss of leadership.
Director — Felicia Williams: The filing discloses the appointment of a new independent director to the board and committees, which is a routine governance action rather than an executive departure.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.